Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...

Credit cards have notoriously high interest rates, so carrying a balance can be costly. However, some cards offer a path to paying off debt quicker with an introductory 0% APR period. These cards ...

Monthly interest payments can be added to the balance, or paid out into an account of your choice. Our ratings take into account a product's rewards, fees, rates and other category-specific ...

Strict editorial guidelines to ensure fairness and accuracy in our coverage to help you choose the financial accounts that work best for you. See our criteria for evaluating banks and credit unions.

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Blueprint Medicines Corp (NASDAQ:BPMC) reported a challenging fourth quarter for 2024, missing analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -0.79, ...